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Introduction
 Competition between innovative and generic pharmaceutical 
companies intensified in last decade
 Macedonia has limited medicines budget and aims to save on 
medicines supplies, but also intends to use innovative medicines for 
first and second-line therapy
 During financial crisis, health authorities promote use of generics 
vs. expensive originator medicines
Study objectives
 Description of circumstances 
that led to innovative 
medicines’ entry to the market
Study methodology
 Analysis of national 
legislation and circumstances 
that influence innovative 
medicines’ entry to the market
Legal acts and by-
laws
Official 
Gazette
(year)
Characteristics of reimbursement policies and medicines 
prices
Law for supplementing 
and amending the Law 
on medicinal products 
and medical devices
88/2010 New paragraph allows by-laws to treat price formation at 
technical details level
Methodology for 
medicines’ single price 
structure 
156/11
45/12
Referent pricing: Slovenia, Bulgaria, Netherlands, Poland, UK, France, 
Croatia, Serbia, Greece, Germany, Turkey and Russia 
Maximum wholesale medicines price: average value of 2 lowest 
comparison wholesale prices from referent countries 
Fees within wholesale medicine price: wholesale fees, custom fees, 
other import fees
Retail margin: as % of wholesale prices (28, 25, 20% up to 1,200 MKD).  
Medicine pricing structure: suggested retail price – same or lower price 
calculated by this methodology
Increase of medicines prices - pharmacoeconomic study and/or 
calculations for justification
Brand medicines or innovative medicines
Maximum price – average value of 2 lowest wholesale prices of brand 
medicine from same manufacturer in referent countries 
Pharmacoeconomics indicators
Legal acts and by-laws Official 
Gazette
Characteristics of reimbursement policies and medicines 
prices
Law for supplementing 
and amending the Law 
on medicinal products 
and medical devices
11/2012 Option given for parallel importation of medicines
Law for supplementing 
and amending the 
Health Insurance Law 
26/2012 Modification of mode and methodology to establish the Health 
Insurance Fund (HIF) medicines reimbursement list (Positive list):
Ordinance passed by Government  
14 expert committees established by Government according to ATC, 
made from 17 members (14 MDs, 1 MOH representative, 1 clinical 
pharmacologist/pharmacist) 1year mandate.
Committees make decisions based on prior opinion given by 
appropriate university clinic. 
Health Insurance Fund 
(HIF) medicines 
reimbursement list 
(Positive list)
81/2012 
revised text
Number of amendments and additions
• medicines dispensed according to INN and ATC classification
• preferences towards generic medicines 
• small number of innovative medicines
• Listed indications for reimbursement 
• 377 medicines on primary care / 343 medicines on hospital 
positive list (by generic name)
Legal acts and by-
laws
Official 
Gazette
Characteristics of reimbursement policies and medicines 
prices
Ordinance on mode 
and methodology for 
HIF medicines 
reimbursement list 
116/ 
2012
Medicines on the list 
• List A – medicines from PHC, dispensed at HIF-contracted pharmacies 
• List B - medicines from hospital healthcare 
• Medicines grouped according to ATC, INN, prescribing regime, 
indications, application site, dispensing of special group medicines, 
dispensing and use of medicines according to indications or remarks 
• Application procedure for adding/removing medicines on list
• Harmonisation with HIF financial possibilities
• Incorporation of scientific evidence on drug efficacy, pharmaco-
therapeutic/pharmaco-economic indicators and medicines price
• Incorporation of pharmaco-economic and financial analysis, wholesale 
prices according to DDD and info on medicines inclusion on positive 
lists in EU countries/other with comparative economic systems
List revision at least annually
Rulebook on the 
criteria and 
procedures to 
establish medicines 
reference prices 
158/09 
138/10 
• Referent countries: Slovenia, Croatia, Bulgaria, Serbia 
• Harmonisation of reference price with PPP coefficient 
• Price of medicine with no generic competitor - max 10%, and with 
generic competitor - max 79,23% of average comparison price 
• Option for therapeutic equivalent with same efficiency/safety 
• Reference prices established on 10 January each year.
Discussion
 By-laws explain medicines pricing and registration procedure (incl. 5% VAT)
 Reference pricing methodology sets low unique medicines prices 
 Only medicines of special interest can be up to 20% higher than average 
wholesale prices in referent countries
 The complexity of positive list’ procedure delays and hampers the inclusion of 
new medicines on the list
 HIF establishes referent prices, and negotiates with companies the price 
alignment of brand medicines and predetermined reference prices of generic 
medicines to achieve lower prices
 National medicines budget reached 154 million Euros
 3510 registered medicines: 2623 generic (75%) and 152 innovative (4%)
Requests for inclusion of innovative medicines on the reimbursement list (2007 – 2012)
ATC code INN Name of the 
medicine
Manufacturer Registration date
L01XA03 oxaliplatin Eloxatin
Oksaliplatin
Aventis farma
Sanofi-Aventis
Cipla Ltd.
EBEWE Pharma
PLIVA LACHEMA as
13.05.2010
30.06.2009
29.03.2012
30.06.2009
L01XC07 bevacizumab Avastin Hoffman la Roche 28.09.2010
L01XE01 imatinib * Glivec
Anzovip
Imakrebin
Plivatinib
NOVARTIS Pharma
ZDRAVLJE A.D. -
Leskovac
REMEDICA Ltd –
Limasol, Cyprus
PLIVA Hrvatska
25.03.2011
25.12.2012
24.01.2013
29.11.2012
L01XE03 erlotinib Tarceva Hoffman la Roche 28.10.2010
L01XC04 alemtuzimab Mabcampath Boehringer
ingelheim
28.10.2010
B01AX06 rivaroxaban Xarleto BAYER SCHERING 
PHARMA AG
30.12.2008
Conclusion and recommendations (1)
Republic of Macedonia has limited drug budget and aims to save the resources 
for drug supplies. 
 It also aims to allow market entrance of innovative medicines, especially for 
first- and second-line treatments in line with its financial possibilities.  
 Regulation has been recently modified to facilitate market entrance for 
innovative medicines. But, frequent modifications and adjustments delayed the 
process of their efficient implementation
 Generic prescribing and reference pricing have a negative impact on brand 
medicines and limit choices of prescribers and patients, but save budget 
resources that can be used to include innovative medicines on the market and 
the reimbursement list.  
Parallel importation is beneficial to market offer, competition and medicines 
prices, but hampers the financial sustainability of the innovative companies’ 
representative offices. 
Conclusion and recommendations (2)
 Discontinued legal procedures and complicated procedures delay its 
completion and inclusion of innovative medicines on the positive list
Reduction of medicines prices with unique prices / reference prices 
methodologies for reimbursed medicines can free resources for new medicines, 
but lower prices decrease innovative companies’ interest to enter the market
Savings can be made by (1) rationale positive list, (2) rational use of medicines 
in hospital and (3) introduction of pharmacoeconomic aspects in practice, which 
can be used to include new medicines for patient care.  
Inclusion of expensive innovative medicines shall be based on scientific 
evidence on drug efficiency (first- and second-line therapies), pharmaco-
therapeutic and pharmaco-economic indicators and HIF financial possibilities. 
Presence of innovative medicines on Macedonian market and inclusion on 
positive list shall be done in line with experience of EU and neighboring 
countries with comparative economic systems
